Genprex doses first patient in Acclaim─3 study of Reqorsa Immunogene Therapy in combo with Tecentriq to treat small cell ...
Genprex, Inc., a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, announced that the first patient has been enrolled and dosed in the company’s phase 1 dose escalation portion of the …